The protective effects of plasma gelsolin on stroke outcome in rats

BACKGROUND: To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Huong T, Hirko, Aaron C, Thinschmidt, Jeffrey S, Grant, Maria, Li, Zhimin, Peris, Joanna, King, Michael A, Hughes, Jeffrey A, Song, Sihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224589/
https://www.ncbi.nlm.nih.gov/pubmed/22047744
http://dx.doi.org/10.1186/2040-7378-3-13

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3224589/
https://www.ncbi.nlm.nih.gov/pubmed/22047744
http://dx.doi.org/10.1186/2040-7378-3-13

Ejemplares similares